DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids
    9.
    发明授权
    DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids 失效
    编码T-1249的DNA和其他可用于治疗辅助物质的病毒融合抑制剂肽

    公开(公告)号:US07297784B2

    公开(公告)日:2007-11-20

    申请号:US10351641

    申请日:2003-01-24

    IPC分类号: C07H21/04 A61K39/21

    摘要: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

    摘要翻译: 本发明涉及最初衍生自增强其所连接的核心多肽的药代动力学性质的各种逆转录病毒包膜(gp41)蛋白质序列的增强子肽序列。 本发明基于以下发现:包含与核心多肽连接的增强子肽序列的杂合多肽具有增强的药代动力学性质,例如增加的半衰期。 本发明还涉及通过将增强子肽序列与核心多肽连接来增强任何核心多肽的药代动力学性质的方法。 用于本发明实践的核心多肽可包括可用于例如治疗或预防试剂的任何药理学上有用的肽。